title: Editorial commentary: What did we learn from the emergency use authorization of peramivir in 2009?
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Pavia
mesh_terms: D000146:Acids, Carbocyclic; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003517:Cyclopentanes / Q000009:adverse effects* / Q000627:therapeutic use*; D004638:Emergency Treatment; D005260:Female; D006146:Guanidines / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy*; D008297:Male; D011247:Pregnancy
chemical_list: D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; C414210:peramivir